NEW YORK (GenomeWeb) – Qiagen has launched the third tranche of a share repurchase program for up to approximately $30 million. 

In a document filed with the US Securities and Exchange Commission, the firm said that a maximum of 2 million shares will be repurchased at a maximum per-share price no greater than 10 percent above the average closing price of the last five trading days prior to the day of purchase on the Frankfurt Stock Exchange. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.